Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly earnings of $1.84 per share which beat the analyst consensus estimate of $1.55 by 18.71 percent. This is a 475 percent increase over earnings of $0.32 per share
Alnylam made more profit per share than expected, which is good—but sold less total product than people thought it would, which is not. When a company's earnings beat but sales miss, it means they're controlling costs well, but growth might be slowing down.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.